drugset
drugset / Trial / NCT05331326

A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

NCT05331326 ↗

Phase 2 Unknown 64 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a multicenter, single-arm phase II clinical trial to evaluate the efficacy and safety of RC48 in metastatic human epidermal growth factor receptor 2 (HER2) expressing breast cancer with abnormal activation of PAM pathway.

Timeline

Start
2022-04
Primary completion
2023-12
Completion
2024-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Disitamab Vedotin Monoclonal antibody 2 mg/kg Intravenous

Indications

breast cancer